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Background: Hypertensive patients (HTs) are usually attended in primary care (PC). We aimed to assess the
diagnostic accuracy and cost-benefit ratio of 24-hour ambulatory blood pressure monitoring (ABPM) in all newly
diagnosed hypertensive patients (HTs) attended in PC.
Methods: In a cross-sectional study ABPM was recorded in all 336 never treated HTs (Office BP ≥140 and/or ≥
90 mm Hg) that were admitted during 16 months. Since benefits from drug treatment in white-coat hypertension
(WCH) remain unproven, a cost benefit estimation of a general use of ABPM (vs absence of ABPM) in HTs was
calculated comparing the cost of usual medical assistance of HTs only diagnosed in office with that based both on
refraining from drug treatment all subjects identified as WCH and on the reduction by half of the frequency of
biochemical exams and doctor visits.
Results: Women were 56%, age 51 ± 14 years and BMI 27 ± 4 Kg/m2. Out of these, 206 were considered as true HTs,
daytime ABPM ≥ 135 and/or ≥85 mm Hg and 130 (38,7%) were identified as having white coat hypertension (WCH),
daytime ABPM <135/85 mm Hg. Versus HTs, WCH group showed higher percentage of women (68% vs 51%) and
lower values of an index composed by the association of cardiovascular risk factors. We estimated that with ABPM total
medical expenses can be reduced by 23% (157.500 euros) with a strategy based on ABPM for 1000 patients followed
for 2 years.
Conclusions: In PC, the widespread use of ABPM in newly diagnosed HTs increases diagnostic accuracy of
hypertension, improves cardiovascular risk stratification, reduces health expenses showing a highly favourable
benefit-cost ratio vs a strategy without ABPM.
Keywords: Hypertension, Ambulatory blood pressure monitoring (ABPM), General practice/Family medicine,
White coat hypertension (WCH), Cardiovascular risk factors, ABPM cost-benefitBackground
Hypertension (HT) is a recognized public health prob-
lem and is considered the leading cause of death
throughout the world [1,2]. It is particularly responsible
for the occurrence of fatal and non fatal cardiovascular
events and deaths, including stroke and coronary heart
disease [1,2]. HT is a chronic disease with an estimated
prevalence of 40-45% in adults [3-5] that in most cases
requires periodic monitoring, non-pharmacological
and pharmacological therapy for a lifetime [1-5]. The* Correspondence: jjpolonia@gmail.com
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reproduction in any medium, provided the ordiagnosis of hypertension is associated with personal,
social and economic disturbances with a noteworthy
impact to the patient, to the health system and to the
society [1-5]. General Practionerrs (GP) have an im-
portant role in the global approach to the hyperten-
sive patient, concerning the diagnosis, treatment and
regular monitoring. Actually, the great majority of the
hypertensive situations are diagnosed and followed by
the GP in primary care. It is now generally recog-
nized that blood pressure (BP) measurement in office
has several limitations. In recent years it has been
shown that the evaluation of BP with ABPM for
24 hours has several advantages as compared to theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and reproducibility and higher predictive value of fatal
and non-fatal cardiovascular events [4,6-15]. Further-
more, ABPM allows multiple BP measurements dur-
ing 24 h that may be more representative of the daily
BP burden, permits the evaluation of BP during the
daily activities away of the BP alert reaction observed
in office and allows the assessment of BP during sleep
[9,11,14,16]. Also, ABPM may identify some BP pro-
files such as the nocturnal fall of BP and the morning
rise of BP, which abnormal patterns have been shown
to be independent predictors of target-organ damage
and of risk of cardiovascular events [17-20]. Besides,
ABPM allows the identification of individuals with
the so called White Coat Hypertension (WCH) who
shows hypertensive values in office but normal BP
outside the doctor’s office [5,10,21,22]. In the absence
of target organ damage, WCH show an estimated
prevalence between 18 and 40% [3,5] is associated
with a low cardiovascular risk [1,14,23-25] for which
evidence of benefit from drug treatment is lacking.
Therefore recent “guidelines” [1] have suggested that,
in the absence of target organ damage or previous
events there is no clear justification to initiate pharmaco-
logic treatment in subjects with WCH although periodic
monitoring (including a ABPM/year) and surveillance is
required. Thus ABPM may be considered an important
technique for evaluation of new hypertensive patients
even in the primary care setting. There are virtually no
studies totally performed in primary care that have so far
evaluated the diagnostic accuracy of the ABPM and its
discriminative value of cardiovascular risk. Thus based on
the identification of WCH with ABPM, the aim of this
study was to assess the diagnostic accuracy and to deter-
mine the cost-benefit ratio of 24-hour ambulatory blood
pressure monitoring (ABPM) in a population of newly di-
agnosed and previously untreated hypertensive patients
(HTs) attended in primary care.
Methods
We conducted a cross-sectional and analytical observa-
tional study consisting on the analysis of the ABPM
results and other clinical variables, taken from all 360
newly hypertensives patients diagnosed from July 2006
to November 2007 by their GP. All patients were fully
observed in the Health Center of São João in Oporto
and ABPM evaluation was performed in all patients be-
fore any treatment was prescribed. All study was carried
out in compliance with the Helsinki Declaration, and its
protocol was approved by the Ethical Committee of
Centro Saude S. Joao, Porto, Faculdade Medicina do
Porto 4/2006 and all patients participated the study
under their written informed consent. The following var-
iables were recorded: office BP, data from ABPM, gender,age, BMI, smoking habits, dyslipidemia, diabetes mellitus
and family history of cardiovascular disease. Office BP
values (phases I and V of Korotkoff ) were redorded in
the left arm with Omron M6 sphygmomanometer (aver-
age of 3 recordings with 5 min apart), using an appropri-
ate bladder, after resting for 10 minutes in a sitting
position and repeated 8–15 days thereafter. For ABPM
data were used a SpaceLabs 90207 device (SpaceLabs
Inc, Redmond, Washington, USA), connected to the
non-dominant arm. Blood pressure was recorded during
a normal working day with intervals of 20/20 minutes
during the daytime (07:00 to 23:00) and of 30/30 minutes
during the nighttime resting period (23:30 to 06:30). The
nocturnal fall of BP was determined by the (average day-
time BP - average nighttime BP)/daytime average BP ×
100. Patients were classified as dippers for nocturnal
systolic BP decline between 10–19,9%, non - dippers for
nocturnal BP decline between 0–9,9%, inverted-dippers
for nocturnal BP decline between <0% and the extreme
dipper for nocturnal BP fall ≥ 20%. Normotension was
defined if casual BP was <140 mm Hg (SBP) and <90 mm
Hg (DBP) and values of the average daytime ambulatory
BP <135 and <85 mm Hg. Hypertension was defined for
casual BP values ≥ 140 and/or 90 mm Hg and average day-
time ambulatory BP ≥ 135 and/or 85 mm Hg. WCH was
defined for casual BP values ≥ 140 and/or 90 mm Hg and
values of average daytime ambulatory BP <135 and
<85 mm Hg. Concerning the presence of cardiovas-
cular risk factors we established an index of overall
risk per patient resulting from the arithmetic sum of
each one (presence = 1, absence = 0) of the following
risk factors: ageing > 65 years in women and > 55 years
in women, obesity (BMI ≥ 30 kg/m2), dyslipidemia i.e.
total cholesterol > 190 mg/dl) and/or HDL-C <46 mg/
dl women and <40 mg/dl men, and/or triglycerides >
150 mg/dl, smoking and family (first and second de-
gree relatives) history of cardiovascular events before
65 years.
We used a model to calculate cost-effectiveness of
ABPM in primary care taking into account the cost of
medical assistance (drug treatment, medical visits and
laboratorial evaluation) of hypertensive patients diag-
nosed in office vs the cost of medical assistance with a
strategy based on use of ABPM hypertensive patients,
allowing to select true hypertensives and subjects with
WCH.
The model was estimated for a total of 1000 patients
diagnosed as hypertensives according to BP measured in
office and followed-up for 2 years with and without in-
formation of ABPM data. The following parameters were
considered: a) Prevalence of WCH in the initial evalu-
ation by ABPM; b) cost of ABPM (65 euros/registration),
c) cost of treatment antihypertensive (0.65 euros/day,
when indicated, d) cost of routine analytical evaluation in
Pessanha et al. BMC Cardiovascular Disorders 2013, 13:57 Page 3 of 6
http://www.biomedcentral.com/1471-2261/13/57hypertensive patients (14.42 euros for each assessment)
and of the minimum number of medical visits (cost 41
euros/visits, e) the cost of medical visits considered min-
imally required i.e. two medical visits and two analytical
evaluations per year for all hypertensives diagnosed in of-
fice without ABPM evaluation and for all true hyperten-
sive patients confirmed by ABPM versus a single visit and
a single analytical evaluation per year for individuals with
WCH), e) gain (savings) estimated in euros for the period
of 2 years using ABPM (avoiding pharmacological treat-
ment in individuals with WCH and half reducing the
number of medical visits and screening summary) minus
the cost of ABPM versus the cost of medical assistance in
all patients diagnosed as hypertensive in the absence of
use of ABPM. The estimation of cost of drug therapy was
based on “Medicinal products for human use for use in
outpatient clinic, INFARMED, Portugal 2006” and the
cost of medical ambulatory visits and of diagnostic proce-
dures was based on Portuguese National Health System
2006 price list of diagnostic techniques [26].
Statistical analysis
The SPSS (Statistical Package for Social Science) version
12.0 was used to perform statistical analysis. Parametric
data are as average of ± SD. We used the chi-square to
compare groups for categorical variables. The differences
between the group of sustained hypertensives and the
group of subjects with white-coat hypertension events
were obtained by statistical parameter using the t test
Student for independent groups, analyzing the following
variables: age, sex, biochemical variables, casual BP, 24-
hour, daytime and nightime records of ABPM. All tests
were considered statistically significant for significance
level (p) <0.05.
Results
Office BP and ABPM evaluations were performed in 360
patients with newly hypertension diagnosed in office,
without antihypertensive medications who were attended
in General Practice/Family Medicine between July 2006
and November 2007 (16 months). Out of these, 24 indi-
viduals were excluded since casual BP in the second
recording day evolve towards normotensive values.
Therefore for this study we included 336 individuals,
56% women, ageing 51 ± 14 (15–82) years, BMI 26.5 ± 4
(17–41) kg/m2; 3.3% were diabetics, 20.8% had BMI >
29.9 kg/m2, 20.2% were smokers, 44.6% had dyslipidemia,
3% had previous strokes and 1% previous coronary even
and 15.5% had a family history of hypertension. After
ABPM we identified 206 as true hypertensive patients
(HTs, 61.3%) and 130 as having white coat hypertension
(WCH, 38.7%). Table 1 summarizes and compares the
clinical characteristics of these two subgroups. Compared
to WCH, the HTs showed significantly higher levels ofcasual BP, mean 24 h, daytime and nighttime ambulatory
pressures, blood pressure on awakening and 24-hour heart
rate. The group of HTs also showed significantly higher
blood levels of triglycerides, and of the composite index
made by the association of various cardiovascular risk
factors. Also, the percentage of males and smokers was
significantly greater in HTs vs WCH groups and there
were not statistically significant differences concerning the
percentage of obese, of diabetics and of patients with
dyslipidemia. As shown, there were no statistically signifi-
cant differences between HTs and WCH regarding age,
BMI, blood levels of fasting glucose and total cholesterol
and HDL-C sub fraction. Also there were no differences
between groups for different patterns of nocturnal decline
in BP. Table 2 shows the calculation of cost of medical re-
sources of either strategies with and without the contribu-
tion of ABPM, estimated for 1000 hypertensive patients
classified with office BP followed for two years. Based on
data from the present study we considered that after
ABPM, WCH would be diagnosed in 38% of the hyperten-
sive patients identified only with office BP. As shown, on
the strategy without ABPM and according to guidelines
[27] all hypertensive patients diagnosed in office as well as
all true hypertensive patients diagnosed with ABPM
should be treated with antihypertensive drugs and submit-
ted per year at least to two doctor visits and to two rou-
tine biochemical evaluations. In contrast follow-up of
subjects with WCH (i.e. 38% of all hypertensive patients
diagnosed in office) could be restrained per year to a
single doctor visit and to a single routine biochemical
evaluation whereas they also should perform an ABPM re-
cording every year. Despite of ABPM strategy involving
the additional cost of this examination we can obtain an
overall saving of about 23% of resources i.e. corresponding
to around 157,500 euros for 1000 patients followed for
two years in general practice.
Discussion
The aim of this study was to evaluate in Primary Care,
the diagnostic value and cost-effectiveness of ABPM in
Primary Care in newly diagnosed hypertensive patients.
Because benefits from drug treatment in white-coat
hypertension (WCH) remain unproven, we estimated
that the avoidance of drug treatment and the reduction
of other medical care expenses in the 38% of the hyper-
tensive patients diagnosed as having WCT would repre-
sent an overall significant saving of medical resources
and cost of therapy if 24-hour ABPM was generalized to
all hypertensive patients diagnosed only on the basis of
casual BP measurements.
The importance of ABPM in the diagnosis, monitoring
and prognostic stratification of hypertensive patients
is clearly defined in literature [1,7-9,11-14,22,28-32].
ABPM is considered a simple and noninvasive technique
Table 1 Anthropometric characteristics and values of
casual blood pressure, ambulatory BP and of biochemical






Age (years) 50 ± 14 52 ± 14 0.27
Women (%) 68 51 <0.05
BMI (kg/m2) 26 ± 4 27 ± 4 0.35
BMI >29.9 Kg/m2 (%) 18 23 0.32
Smokers (%) 14 24 <0,01
Dyslipidemia (%) 38 47 <0.05
Diabetes (%) 2.3 3.9 0.19
Family history of CV disease (%) 13 20 0.23
Office SBP (mm Hg) 154 ± 12 161 ± 15 <0,001
Office DBP (mm Hg) 92 ± 10 94 ± 9 <0,05
24 h SBP (mm Hg) 120 ± 6 135 ± 10 <0,001
24 h DBP (mm Hg) 73 ± 5 85 ± 7 <0,001
24 h PP (mm Hg) 47 ± 6 51 ± 9 <0,001
24 h Heart rate (beats/min) 73 ± 9 77 ± 9 <0,001
Daytime SBP (mm Hg) 124 ± 6 140 ± 10 <0,001
Daytime DBP day (mm Hg) 77 ± 5 89 ± 8 0.052
Nighttime SBP (mm Hg) 113 ± 8 126 ± 12 <0,001
Nighttime DBP day (mm Hg) 66 ± 6 76 ± 8 <0,001
Nocturnal SBP fall (%) 8,7 ± 5,6 10,1 ± 5,6 <0,05
Inverted-dipper (%) 2 4 0.44
Non-dipper (%) 43 46 0.62
Dipper (%) 46 47 0.71
Extreme-dipper (%) 9 3 0.11
SBP on awakening (mm Hg) 116 ± 15 134 ± 17 <0,001
Total Cholesterol (mg/dl) 216 ± 37 220 ± 39 0.12
HDL-C (mg/dl) 58 ± 15 54 ± 17 0.14
Tryglicerides (mg/dl) 128 ± 83 160 ± 124 <0,05
Glicemia (mg/dl) 95 ± 19 101 ± 26 0.09
numRF (n) 1,15 ± 0,90 1,44 ± 0,98 <0,05
Values expressed as average ± standard deviation.
WCH White Coat Hypertensive, HTS Sustained Hypertensive, BMI Body Mass
Index, SBP Systolic blood pressure, DBP Diastolic blood pressure, HR heart rate;
PP Pulse Pressure, numRF Number of risk factors, p level of significance.
Table 2 Reducing costs on medical resources with the use of
















Without ABPM 100% 474500 164000
With ABPM 62% 294190 132840
% ABPM saving strategy
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providing exclusive data on the blood pressure profile in
real life outside the medical office [1,7-9,11-14,22,28-32].
ABPM is a valuable tool for the diagnosis of masked hyper-
tension a condition cursing with normotensive values
in office and abnormally high pressure values outside
the office setting that has been associated with an in-
creased incidence target organ damage [33]. ABPM
also allows to identify those individuals with white
coat hypertension/isolated office hypertension (WCH)
[1,4,6,12,16,21,24,34,35] who exhibit a high blood pre-
ssure values in the doctor’s office in contrast with
normal blood pressure values outside that setting.
WCH cannot be diagnosed reliably on clinical exam-
ination alone. Both ABPM and home blood pressure
monitoring (HBPM) overcomes many of the limita-
tions of traditional office blood pressure (BP) meas-
urement and are the mostly used tools for the
diagnosis of white-coat hypertension [1]. Home read-
ings are more reproducible than office readings and
show better correlations with measures of target
organ damage [12]. Since it is less influenced by the
white-coat effect HBPM contributes for the diagnosis
of WCH. However, using ABPM as a reference, it has
been shown a lower accuracy, specificity and sensitiv-
ity of HBPM to detect white coat hypertension [36]
and that HBPM may not be completely devoid of
white-coat effects [37]. Although there are some po-
tential cost-effectiveness advantages for the use of
HBPM in the diagnosis and management of hyperten-
sion by reducing the need for office visits, the net
cost of home blood pressure monitorings and the ab-
sence of reimbursement by National Health Systems,
as it occurs in Portugal, limits it generalization to a
broad population and threatens its potential cost-
effectiveness [38]. WCH has been associated with a
low cardiovascular risk profile at least while compar-
ing to sustained hypertensives [1,4,8,11,14,23-25,39].
Careful surveillance and implementation of healthy
lifestyles but not pharmacological therapy has been
recommended in WCH [1,4,24,25] and no study has
so far clearly proven that drug treatment provides any
benefit. Thus, the identification of WCH may have












57680 0 696180 0
46721 65000 538751 157429
22,6%
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the need of medical visits and exams [40]. Almost all
studies using 24 hours ABPM have been made so far
in hospitals. i.e. outside the Primary Health Care
Centers. Since hypertension is highly prevalent in
general adult population (about 40% of adult popula-
tion) most patients are diagnosed, evaluated and
followed in general practice. In our study, for the estima-
tion of the diagnostic value and cost-effectiveness of
ABPM in Primary Care we evaluated clinically and with
ABPM 336 adult patients with newly diagnosed office
hypertension, that in 38.7% were fulfilling the diagnosis of
white coat hypertension. This percentage of WCH as well
as a higher number of women in this group is consistent
with that found in the literature [3,5,12,13] particularly
concerning the hypertensive population with stage 1 and 2
hypertension at the office, i.e. the population that is more
frequently observed in Primary Health Care. For a similar
age and BMI distribution, the group of individuals with
sustained hypertension shoed higher casual blood pressure
and 24-hour ABPM values comparing to WCH. True
hypertensives also showed a worse profile of global cardio-
vascular risk as expressed in the coexistence of a cumula-
tive aggregate of cardiovascular risk factors, beyond the
office BP levels. Also, office BP and ABPM values were
higher in HTs individuals than in those with WCH. Thus,
the present study confirms that patients with WCH show
several indicators of a lower cardiovascular risk than
patients with sustained hypertension. There is now con-
sensus that individuals with WCH require medical super-
vision but benefit from pharmacological treatment is
unproven [1,24,25,29]. Thus the diagnosis of this condi-
tion could have important implications in reducing health
expenses on medication, medical visits and diagnostic
exams that could result in the reduction of iatrogenic risks
and of direct and indirect (personal, family and social,
etc.) costs.
In the present study we estimated the cost benefit of
two strategies of monitoring of newly diagnosed hyper-
tensive patients based and not based on the general use
of 24-h BPM in Primary Health Care. With ABPM we
were able to identify 38% of the hypertensive patients
diagnosed in office as having WCT. Although ABPM
strategy implied an increased cost related with general-
ized 24-h BP monitoring procedure, there was a signifi-
cant saving of medical resources and cost of therapy
since these subjects were not only restrained from drug
treatment but also doctor visits and routine biochemical
evaluation were reduced by half as compared with
sustained hypertensives.
Considering the high prevalence of the WCH found in
the newly diagnosed hypertensive population, our study
clearly suggests that the implementation of a strategy of
widespread use of ABPM in Primary Care provides ahighly favourable cost-benefit ratio. Our estimation for
1000 patients followed for 2 years showed that it is pos-
sible to reduce about 23% of total medical expenses with
a strategy based on ABPM vs no use of ABPM. In other
words ABPM based strategy reduced overall expenses by
157.500 euros per 1000 patients evaluated for two years.
These data agree to those of other studies in which
ABPM showed a favourable benefit-cost ratio for opti-
mizing therapy [24,40] and for reducing the number of
antihypertensive drugs needed in patients with sustained
hypertension under chronic treatment [41]. Meanwhile,
our estimation did not take into account any additional
gain resulting from the avoidance of possible drug side
effects and iatrogenic related costs associated with the
massive and widespread use of medication in subjects
for whom the benefits of therapy have not been proved.
Our study has limitations. Beyond the factor related with
the relatively small dimension of our sample it is generally
assumed that 24-h ABPM is not easily available to all
Private care Doctors thereby limiting the generalization of
this method. Secondly it is not clear whether subjects with
WCH who has concomitant other risk factors beyond of-
fice hypertension or underlying diseases do not require
the immediate start of anti-hypertensive treatment. Also
in our study there was another expected inconvenience
related to a possible misdiagnosis of hypertension at entry
while based only in casual BP evaluation that could lead
to the inclusion in the WCH group some real normoten-
sive subjects.
Conclusions
In conclusion our study shows that in Primary Health
Care, the strategy based on the widespread use of 24-
hour ABPM in newly diagnosed hypertensive patients
has a highly favourable benefit-cost ratio in comparison
with a strategy without ABPM. The former strategy al-
lows to reduce by 23% the overall costs associated with
the implementation of therapy and of medical diagnosis
and monitoring procedures. Our data may support the
widespread implementation of the ABPM technique in
general medicine/family practice within the approach of
newly hypertensive patients, by contributing to increase
diagnostic accuracy of hypertension, to improve risk
stratification and to reduce the costs and the iatrogenic
drug risks.
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